Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up

Conclusion.With a longer follow‐up of almost 5 years, combination of weekly paclitaxel, trastuzumab, and pertuzumab remains effective with a favorable median PFS and a median OS not reached.Implications for Practice.The combination of weekly paclitaxel, trastuzumab, and pertuzumab has been endorsed by the National Comprehensive Cancer Network as one of the first‐line treatment options in patients with human epidermal growth receptor 2 (HER2)‐positive metastatic breast cancer (MBC). However, the long‐term safety and efficacy are still unknown. Findings from this phase II study provide favorable preliminary data on the safety and efficacy of trastuzumab and pertuzumab in combination with weekly paclitaxel at 5‐year follow‐up, and it remains an effective first‐line treatment option for patients with HER2‐positive MBC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research

Related Links:

Conditions:   Advanced Breast Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Germlin e BRCA1 Gene Mutation;   Germline BRCA2 Gene Mutation;   HER2/Neu Negative;   Metastatic Breast Carcin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: 2019Source: European Journal of Radiology Open, Volume 6Author(s): Taiyo L. Harada, Kazuaki Nakashima, Takayoshi Uematsu, Takashi Sugino, Seiichirou Nishimura, Kaoru Takahashi, Yukiko Tadokoro, Tomomi Hayashi, Junichiro Watanabe, Shogo NakamotoAbstractA 63-year-old woman was referred to our hospital for breast cancer treatment. She had a large HER2-positive breast tumor on her left breast, and received neoadjuvant chemotherapy. After treatment, a shrunk spiculated mass with calcification-like high density was detected on mammography, and MRI revealed a large strong susceptibility artifact. Surgical specim...
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
AbstractPurposeLiterature on the separate effects of physical activities (PA) on risk of breast cancer (BC) sub-types is heterogeneous. We investigated domain-specific associations between PA and BC risk by menopausal status and molecular subtype.Methods1389 histologically confirmed invasive BC cases and 1712 controls from the MCC-Spain study were included (age: 20 –85 years). Questionnaire information on PA at work, at home, and during leisure time, including recreational PA and sedentary time, and data on reproductive history, anthropometry, family history of BC, diet, and lifestyles were obtained through face...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionPremenopausal Asian women with breast cancer have unique disease characteristics and may benefit from treatment that differs somewhat from international guidelines. Given the great diversity of patients and clinical settings worldwide, the ABCCG advocates evidence-based yet flexible and individualized use of all potential options to improve breast cancer outcomes.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeGene expression profiling (GEP) test scores calculate risks of recurrence and likely benefit of adjuvant chemotherapy in ER-positive, HER2-negative, early-stage breast cancer. As health literacy and numeracy skills in the general population are poor, healthcare professionals (HCPs) require a wide repertoire of communication skills to explain clearly risk of recurrence scores (RSs) and uncertainty. We developed and evaluated an educational program for HCPs discussing GEP test results and adjuvant treatment.MethodsEight-hour workshops contained elements aimed at improving knowledge, communication skills and se...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionPreoperative CEA and CA15-3 levels showed varying prognostic ability according to breast cancer subtype. Preoperative CA15-3 and CEA elevation are significant prognostic factors for luminal breast cancer, but they were not significant factors for TNBC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
In this study, we explored the role of MPO-positive cell infiltration and its prognostic significance in invasive breast cancer.MethodsWe performed immunohistochemical staining for MPO on multiple tissue microarrays comprising a total of 928 human breast cancer samples with detailed clinical-pathological annotation and outcome data.ResultsMPO-positive cell infiltration ( ≥ 5 cells/tissue punch) was found in 150 (16%) of the 928 evaluable breast cancer cases. In univariate survival analyses, infiltration by MPO-positive cells was associated with a significantly better overall survival (p 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsThere is modest correlation in continuous gene expression, as measured by the RS and single-gene results for ER, PR, and HER2 between paired primary tumors and synchronous nodal metastases. RS testing for ER+ breast cancer should continue to be based on analysis of primary tumors.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Roche today announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in peo ple with HER2-positive early breast cancer (eBC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Hoskin Many dietary flavonoids possess anti-cancer activities. Here, the effect of apple peel flavonoid fraction 4 (AF4) on the growth of triple-negative (MDA-MB-231, MDA-MB-468), estrogen receptor-positive (MCF-7), and HER2-positive (SKBR3) breast cancer cells was determined and compared with the effect of AF4 on normal mammary epithelial cells and dermal fibroblasts. AF4 inhibited breast cancer cell growth in monolayer cultures, as well as the growth of MCF-7 spheroids, without substantially affecting the viability of non-malignant cells. A sub-cytotoxic concentration of AF4 suppressed the proliferation of MDA-MB-23...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Study